中成药2017，Vol.39Issue(7)：1336-1341,6.DOI:10.3969/j.issn.1001-1528.2017.07.002
表没食子儿茶素没食子酸酯对顺铂诱导大鼠肾损伤的改善作用
Improving effects of epigallocatechin gallate on rat kidney injury induced by cisplatin
摘要
Abstract
AIM To investigate the improving effects of epigallocatechin gallate (EGCG) on rat kidney injury induced by cisplatin and its mechanism of action.METHODS Fifty male SD rats (10 rats/group) were randomly divided into blank control group,kidney injury group,EGCG low-,middle-and high-dose (25,50 and 100 mg/kg) groups.The kidney injury group and the drug administration group were treated with 7.5 mg/kg cisplatin by intraperitoneal injection to build the kidney injury model,and the blank control group was intraperitoneally injected with normal saline.After fourteen days of administration,the general condition and morphological changes of kidney tissue by HE staining were observed;BUN,Cr,Cys-c contents in serum,and IL-18,KIM-1 contents in urine were detected by ELISA;MDA,GSH and T-SOD contents in renal cortex were determined by kit;Western blot method was used to determine the contents of Nrf2 protein in renal contex cytoplasm and nucleus,and the expression level of HO-1 protein.RESULTS EGCG intervention could improve the pathological structural changes of rat kidney injury induced by cisplatin,decrease kidney index,and decrease serum Cr,Cys-c contents and urine IL-18,KIM-1 contents.Moreover,renal cortex MDA concentration decreased,and renal cortex GSH concentration,T-SOD activity increased.At the same time,renal cortex cytoplasm Nrf2 content reduced,but nucleus Nrf2 and total cell HO-1 contents increased.CONCLUSION EGCG plays a role in the improvement of rat kidney injury induced by cisplatin through the activation of Nrf2/HO-1 signal pathway.关键词
表没食子儿茶素没食子酸酯/顺铂/肾损伤/Nrf2/HO-1信号通路Key words
epigallocatechin gallate/cisplatin/kidney injury/Nrf2/HO-1 signal pathway分类
医药卫生引用本文复制引用
王凤仙,杨伟,高春华,张诗缇,胡相卡,陈香,代春美..表没食子儿茶素没食子酸酯对顺铂诱导大鼠肾损伤的改善作用[J].中成药,2017,39(7):1336-1341,6.基金项目
辽宁省教育厅一般科学研究项目(L2014322) （L2014322）
中国博士后科学基金项目(2015M571251) （2015M571251）
锦州医科大学横向课题(LY-HX2013033) （LY-HX2013033）
